IL6 and thrombophilia: Another plausible explanation of the hypercoagulability in patients with COVID‐19 is the presence of high levels of interleukin‐6 (IL‐6) and supported by the potential benefit of IL‐6 inhibitors like tocilizumab in severe COVID‐19 patients.26, 28